达沙替尼
医学
伊马替尼
慢性粒细胞白血病
内科学
费城染色体
肿瘤科
不利影响
药理学
白血病
髓系白血病
染色体易位
生物化学
化学
基因
标识
DOI:10.1586/14737140.7.11.1529
摘要
Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. Clinical trials have demonstrated its activity across all phases of CML. Dasatinib was superior to high-dose imatinib in a randomized, Phase II study of patients with chronic-phase CML who were resistant or intolerant to imatinib. Preliminary data from a Phase II trial in patients with previously untreated CML suggests that dasatinib compares favorably with imatinib in first-line use. Adverse events experienced with dasatinib include myelosuppression and fluid retention (e.g., pleural effusions), which were manageable with dose adjustment or treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI